Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
gptkb:casirivimab
|
| gptkbp:approvedBy |
gptkb:EMA
gptkb:FDA_(Emergency_Use_Authorization) 2020 |
| gptkbp:ATCCode |
gptkb:J06BD08
|
| gptkbp:brand |
gptkb:Ronapreve
gptkb:REGEN-COV |
| gptkbp:CASNumber |
2421386-32-2
|
| gptkbp:combinationTherapy |
casirivimab and imdevimab
|
| gptkbp:developedBy |
gptkb:Regeneron_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
imdevimab
|
| gptkbp:indication |
post-exposure prophylaxis of COVID-19
treatment of mild to moderate COVID-19 |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
IgG1 monoclonal antibody
|
| gptkbp:mechanismOfAction |
neutralizes SARS-CoV-2 virus
|
| gptkbp:routeOfAdministration |
subcutaneous
intravenous |
| gptkbp:sideEffect |
nausea
rash allergic reactions infusion-related reactions |
| gptkbp:target |
gptkb:SARS-CoV-2_spike_protein
|
| gptkbp:UNII |
6QY1D9K2TI
|
| gptkbp:usedFor |
gptkb:COVID-19
|
| gptkbp:bfsParent |
gptkb:REGEN-COV_(casirivimab_and_imdevimab)
gptkb:REGEN-COV |
| gptkbp:bfsLayer |
7
|